Preux Céline, Bertin Marion, Tarot Andréa, Authier Nicolas, Pinol Nathalie, Brugnon David, Pereira Bruno, Guastella Virginie
Palliative Care Center, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
Neuro-Dol, Service Pharmacologie Médicale, Centres d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, CHU Clermont-Ferrand, Université de Clermont Auvergne, F-63001 Clermont-Ferrand, France.
J Clin Med. 2022 Mar 14;11(6):1594. doi: 10.3390/jcm11061594.
The opioid use disorder is an international public health problem. Over the past 20 years it has been the subject of numerous publications concerning patients treated for chronic pain other than cancer-related. Patients with cancer-related pain are also at risk of opioid use disorder. The primary objective of this literature review was to determine the prevalence of opioid use disorder in patients with cancer-related chronic pain. Its secondary objective was to identify the characteristics of these opioid users.
This is a literature review of studies published over the last twenty years, from 1 January 2000 to 31 December 2020 identified by searching the three main medical databases: Pubmed, Cochrane, and Embase. A meta-analysis took account of between and within-study variability with the use of random-effects models estimated by the DerSimonian and Laird method.
The prevalence of opioid use disorder was 8% (1-20%) and of the risk of use disorder was 23.5% (19.5-27.8%) with values of 97.8% and 88.7%, respectively.
Further studies are now needed on the prevalence of opioid use disorder in patients treated for cancer-related chronic pain. A screening scale adapted to this patient population is urgently needed.
阿片类物质使用障碍是一个国际公共卫生问题。在过去20年里,它一直是众多关于非癌症相关慢性疼痛患者治疗的出版物的主题。患有癌症相关疼痛的患者也有阿片类物质使用障碍的风险。这篇文献综述的主要目的是确定癌症相关慢性疼痛患者中阿片类物质使用障碍的患病率。其次要目的是确定这些阿片类使用者的特征。
这是一篇对过去二十年(2000年1月1日至2020年12月31日)发表的研究的文献综述,通过检索三个主要医学数据库:PubMed、Cochrane和Embase来确定。一项荟萃分析考虑了研究间和研究内的变异性,采用DerSimonian和Laird方法估计的随机效应模型。
阿片类物质使用障碍的患病率为8%(1%-20%),使用障碍风险为23.5%(19.5%-27.8%),I²值分别为97.8%和88.7%。
现在需要对接受癌症相关慢性疼痛治疗的患者中阿片类物质使用障碍的患病率进行进一步研究。迫切需要一种适用于该患者群体的筛查量表。